Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–27 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Chronic Cough Clear all
Completed Phase 2 Interventional Results available

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

NCT02612623
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
Gefapixant, Placebo (for gefapixant)
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Mission Viejo, California • San Jose, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 4, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

NCT05628740
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]
Drug
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 4, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Internet-Behavioral Cough Suppression Therapy

NCT05770401
View directory record Official record
Conditions
Cough, Chronic Disease
Interventions
Internet-Behavioral Cough Suppression Therapy, Sham Treatment
Behavioral
Lead sponsor
University of Montana
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 4, 2026, 4:42 AM EDT